Overview

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Everolimus will be given to patients with metastatic breast cancer who already has a progress taking Everolimus but with a change in the endocrine treatment.
Phase:
Phase 3
Details
Lead Sponsor:
German Breast Group
Collaborator:
Novartis
Treatments:
Everolimus
Exemestane
Sirolimus